Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ester Simeone
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Clinical Cases #33 - Nivolumab in un melanoma cutaneo del dorso recidivante
Andare in bici, per un oncologo come me, è una metafora della bellezza e delle difficoltà del nostro lavoro.
Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
Immune checkpoints represent a significant target in the treatment of metastatic melanoma. They have a crucial role in the maintenance of self-tolerance. Normally, they control the immune system through coinhibitory and costimulatory signals. Coinhibitory checkpoint molecules include CTLA-4, PD-1, LAG-3 and Tim-3, while CD137, OX40 and CD40 are examples of costimulatory molecules. Checkpoint inhibitors allow the potentiation of T-cell specific immune responses against tumor cells.
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600E BRAF inhibitor): a case report
To the best of our knowledge, there are no data available for the use of BRAFi in controlling LM from melanoma. The only clinical evidence provided for such types of drugs has been regarding their effectiveness on brain metastases [7–9]. Although unknown, the effect of BRAFi on LM may be due to different molecular mechanisms. Preclinical studies on such lesions showed the involvement of at least two important processes: angiogenesis and proliferation [13–18]. Reijneveld et al.
Serious haematological toxicity during and after ipilimumab treatment: a case series
Haematological toxicity may potentially involve all blood cell types due to autoimmunity, but the three patients described here have anaemia and/or leukopenia (neutropenia) with toxicity of various grades without significant changes to other haematological values. Two of the patients stopped treatment after the third ipilimumab dose, one because of severe anaemia that required blood transfusion and the other due to febrile neutropenia that was treated with antibiotics and GM-CSF stimulation.
Anti-PD-1 and PD-L1 antibodies in metastatic melanoma
E Simeone received honoraria from BMS, Novartis and Roche Genentech. E Simeone had consultant/advisory role for BMS. PA Ascierto received research founding form BMS, Roche-Genentech, Array Biopharma, and had consulting/advisory role for BMS, Roche-Genentech, MSD, Novartis, Array Biopharma, Amgen, Merck Serono, Pierre Fabre.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ester
Contact Ester, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack